# Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

> **NCT01513174** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spanish Lung Cancer Group** · enrollment: 186 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT01513174
- **Lead sponsor:** Spanish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513174, "Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01513174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*